Ion Exchange Resin Patents (Class 424/78.1)
-
Patent number: 11572355Abstract: The present disclosure provide synthetic methods for the synthesis of N-substituted vinylidene and alkene compounds in addition to compounds formed from such methods.Type: GrantFiled: May 17, 2021Date of Patent: February 7, 2023Assignee: The Board of Trustees of The University of AlabamaInventors: Jason Edward Bara, Kathryn Elizabeth O'Harra
-
Patent number: 11554137Abstract: A composition and method useful in promoting healing of a bleeding wound site. The composition preferably includes a substantially anhydrous acid form of a cation exchange resin, which when applied over blood, provides an antimicrobial against planktonic microorganisms and biofilms in the wound. The resin is also capable, when applied in sufficient quantities, of providing a continuing and persistent antimicrobial against planktonic microorganisms and biofilms through dehydration and ion exchange with cations present in the blood and other body fluids. When the resin has a concentration of at least 26 mg/ml, it provides a >3 log reduction in biological activity of MRSA, MRSE and Pseudomonas aeruginosa.Type: GrantFiled: January 3, 2014Date of Patent: January 17, 2023Assignee: Biolife, L.L.C.Inventors: John Hen, John Alfred Thompson, Talmadge Kelly Keene, Mark Travi
-
Patent number: 11142603Abstract: The present application relates to a commercially viable process for the preparation of Patiromer, a crosslinked polymer. More particularly the present application relates to a commercially viable process for the preparation of Patiromer sorbitex calcium, an active ingredient useful in the treatment of hyperkalemia.Type: GrantFiled: May 9, 2019Date of Patent: October 12, 2021Assignee: Solara Active Pharma Sciences LimitedInventors: Sivadas Anand, Sarita Mohan Pavaskar, Bheemashankar Kulkarni
-
Patent number: 11123465Abstract: The present disclosure is directed to methods of removing proteins, including cytokines, from blood and blood products, the methods comprising contacting the blood or blood product with a form of carbon having high graphitic contents and slit-shaped mesopores and macropores, the pore size dimensions chosen to be comparable to the size of the proteins, wherein the contacting results in the removal of high levels of the protein from the blood or blood product in minutes or hours.Type: GrantFiled: May 26, 2017Date of Patent: September 21, 2021Assignee: Drexel UniversityInventors: Yury Gogotsi, Vadym Mochalin, Nicholas Pescatore
-
Patent number: 10897896Abstract: Embodiments of the invention include stable compositions comprising: an active ingredient, a dispersant, a latex, and water, wherein the active ingredient and the latex in the composition remain substantially separate. Further embodiments include methods of applying the compositions to an area to control undesirable plant growth, fungal pathogens or insects.Type: GrantFiled: December 13, 2012Date of Patent: January 26, 2021Assignee: Dow AgroSciences LLCInventors: Melissa G. Olds, Holger Tank, Toshiya Ogawa
-
Patent number: 10617813Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: November 18, 2015Date of Patent: April 14, 2020Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10398662Abstract: The present application relates to GHB formulations and methods for manufacturing the same.Type: GrantFiled: February 18, 2016Date of Patent: September 3, 2019Assignee: JAZZ PHARMA IRELAND LIMITEDInventors: Clark Allphin, Scott Bura
-
Patent number: 10137151Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: GrantFiled: April 17, 2015Date of Patent: November 27, 2018Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 9815051Abstract: A method of preparing a trihalide resin, where a trihalide ion solution is contacted with a styrene divinylbenzene polymer resin having polymer bonded -ER3+ X? groups where E is N, P, or As, R is a C2-C6 hydrocarbon group and X is Cl, Br, or I. The trihalide ion can be Cl3?, Br3?, or I3?. The trichloride resin can be used as a solid equivalent of chlorine gas. Formation of the styrene divinylbenzene resin comprising -ER3+Cl? units can be used to scavenge chlorine from a gas or liquid to form the styrene divinylbenzene resin comprising -ER3+Cl3? units. The trihalide resins can be used in disinfecting and as a source of a reagent for chemical synthesis.Type: GrantFiled: July 15, 2016Date of Patent: November 14, 2017Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: David Ernest Richardson
-
Patent number: 9770170Abstract: The present invention relates generally to the diagnosis, treatment, and monitoring of Chronic Inflammatory Response Syndrome (CIRS), kits for use in the methods, and pharmaceutical compositions for use in the methods of treatment. The invention specifically relates to the diagnosis, treatment and monitoring of CIRS through a comprehensive approach comprising an assessment of a subject for case definition parameters and a proteogenomic analysis. The proteogenomic analysis for the diagnosis, treatment, and monitoring of CIRS is based on identifying proteins and/or genes that are differentially expressed in subjects suffering from CIRS compared to healthy subjects.Type: GrantFiled: August 7, 2013Date of Patent: September 26, 2017Inventors: Ritchie Shoemaker, Jimmy Ryan
-
Patent number: 9408868Abstract: The present invention relates to a skin external composition comprising a combination of salt and sugar as an active ingredient in an amount effective to treat and prevent vaginosis, together with a pharmaceutically acceptable carrier, and the use thereof.Type: GrantFiled: September 12, 2013Date of Patent: August 9, 2016Inventor: Won Seog Choi
-
Patent number: 9393558Abstract: A method of preparing a trihalide resin, where a trihalide ion solution is contacted with a styrene divinylbenzene polymer resin having polymer bonded -ER3+X? groups where E is N, P, or As, R is a hydrocarbon group and X is Cl, Br, or I. The trihalide ion can be Cl3?, Br3? or I3?. A trichloride resin and a method of preparing the trichloride resin, where a styrene divinylbenzene polymer resin having polymer bonded -ER3+Cl? groups is contacted with chlorine. The trichloride resin can be used as a solid equivalent of chlorine gas. Formation of the styrene divinylbenzene resin comprising -ER3+Cl? units can be used to scavenge chlorine from a gas or liquid to form the styrene divinylbenzene resin comprising -ER3+Cl3? units.Type: GrantFiled: August 13, 2013Date of Patent: July 19, 2016Inventor: David Ernest Richardson
-
Patent number: 9359518Abstract: The invention provides an aqueous binder for granular and/or fibrous substrates, said binder comprising, as active constituents, a polyamine and a saccharide compound.Type: GrantFiled: November 19, 2012Date of Patent: June 7, 2016Assignee: BASF SEInventors: Michael Kalbe, Holger Schilling, Kathrin Michl, Andreas Pfau
-
Patent number: 9205094Abstract: Compositions comprising a therapeutically effective amount of at least one bile acid sequestrant are disclosed for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. Exemplary bile acid sequestrants include colesevelam, colesevelam hydrochloride, colestipol, sevelamer and combinations thereof. The disclosed methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor.Type: GrantFiled: December 21, 2007Date of Patent: December 8, 2015Assignee: IRONWOOD PHARMACEUTICALS, INC.Inventor: Mark G. Currie
-
Patent number: 9173858Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.Type: GrantFiled: November 16, 2012Date of Patent: November 3, 2015Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de BordeauxInventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
-
Patent number: 9105402Abstract: A method of storing charge comprising the steps of providing a capacitor comprising an anode, a cathode, and an electrolyte, wherein the electrolyte comprises a nonaqueous liquid of sufficient dielectric constant to dissociate salts soluble in the nonaqueous liquid, a composite comprising a prefabricated porous carbon electrode structure or a carbon foam substrate that is a prefabricated paper structure and a coating deposited by infiltrating the structure with iron oxide via self-limiting electroless deposition on the surface.Type: GrantFiled: December 16, 2014Date of Patent: August 11, 2015Assignee: The United States of America, as represented by the Secretary of the NavyInventors: Megan B. Sassin, Jeffrey W. Long, Debra R. Rolison
-
Patent number: 9044435Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: September 11, 2014Date of Patent: June 2, 2015Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150132245Abstract: The present invention comprises a method for detoxification or measurement of the concentration of at least one compound in a host body, wherein said host body comprises a sorption material of at least one phase over a certain period of time, where sorption of said at least one compound in at least one phase of said sorption material is effected and the content of the at least one compound in said sorption material is optionally analysed. Use of a sorption material for providing an estimate of the concentration of compounds present in a host body, use of a sorption material for detoxification and sorption material for diagnostic use is also comprised in the present application.Type: ApplicationFiled: April 25, 2013Publication date: May 14, 2015Inventors: Kevin V. Thomas, Katherine Hailey Langford, Alfhild Kringstad, Ian John Allan
-
Publication number: 20150110886Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Gerrit Klaerner, Lance Berman
-
Publication number: 20150104510Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.Type: ApplicationFiled: July 9, 2014Publication date: April 16, 2015Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner
-
Patent number: 8992903Abstract: The invention relates to a cosmetic composition comprising at least one non-elastomer, filmogenic, linear, sequenced, ethylenic polymer and in a cosmetically acceptable liquid medium and a gelling agent of said organic liquid medium. The invention also relates to the combination of said sequenced polymer and a gelling agent in order to improve the texture and application of said composition on keratin fibers.Type: GrantFiled: September 26, 2003Date of Patent: March 31, 2015Assignee: L'OrealInventors: Xavier Blin, Véronique Ferrari
-
Publication number: 20150086501Abstract: Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.Type: ApplicationFiled: July 29, 2014Publication date: March 26, 2015Inventors: Jonathan L. Sessler, Christopher W. Bielawski, Abdullah Aydogan, Daniel J. Coady
-
Patent number: 8986668Abstract: A method of manufacturing a nicotine delivery product comprising nicotine and a cation exchange resin. More precisely, to a method for preparing a nicotine delivery product said method comprising (a) mixing nicotine, a cation exchange resin, an organic polyol and water to form a mixture wherein the total amount of water is from 26 to 45% by weight of the total mixture, and (b) removing water from the mixture to produce said nicotine delivery product.Type: GrantFiled: June 1, 2006Date of Patent: March 24, 2015Assignee: Fertin Pharma A/SInventor: Carsten Andersen
-
Publication number: 20150024059Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.Type: ApplicationFiled: October 7, 2014Publication date: January 22, 2015Inventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8911977Abstract: Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications.Type: GrantFiled: March 13, 2013Date of Patent: December 16, 2014Assignee: E. I. du Pont de Nemours and CompanyInventors: Mark Scott Payne, Robert DiCosimo
-
Patent number: 8888732Abstract: An intraluminal sleeve system is provided, which generally includes an intraluminal sleeve capable of dispensing an active agent to a patient, for example, a metabolic agent or satiety inducing agent. The intraluminal sleeve may be structured to contain the active agent and permit controlled release of the active agent to the patient while the intraluminal sleeve is positioned within the patient's intestine. Methods for treating obesity are also provided which include positioning an intraluminal sleeve in a patient's intestine, the intraluminal sleeve being capable of dispensing an active agent to the patient. In one embodiment, the active agent may be contained in a reservoir and dispensed to a portion of the patient's body.Type: GrantFiled: March 11, 2011Date of Patent: November 18, 2014Assignee: Apollo Endosurgery, Inc.Inventors: Joseph S. Raven, Janel A. Birk
-
Patent number: 8865437Abstract: Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications.Type: GrantFiled: March 13, 2013Date of Patent: October 21, 2014Assignee: E. I. du Pont de Nemours and CompanyInventors: Mark Scott Payne, Robert DiCosimo
-
Patent number: 8865435Abstract: Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications.Type: GrantFiled: March 13, 2013Date of Patent: October 21, 2014Assignee: E. I. du Pont de Nemours and CompanyInventors: Mark Scott Payne, Robert DiCosimo
-
Patent number: 8865436Abstract: Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications.Type: GrantFiled: March 13, 2013Date of Patent: October 21, 2014Assignee: E. I. du Pont de Nemours and CompanyInventors: Mark Scott Payne, Robert DiCosimo
-
Publication number: 20140286891Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.Type: ApplicationFiled: June 4, 2014Publication date: September 25, 2014Inventors: Dominique Charmot, Han-Ting Chang, Gerrit Klaerner, Jerry M. Buysse, Mingjun Liu
-
Patent number: 8841098Abstract: Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications.Type: GrantFiled: March 13, 2013Date of Patent: September 23, 2014Assignee: E.I. du Pont de Nemours and CompanyInventors: Mark Scott Payne, Robert DiCosimo
-
Patent number: 8802074Abstract: Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.Type: GrantFiled: November 23, 2009Date of Patent: August 12, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Christopher W. Bielawski, Abdullah Aydogan, Daniel J. Coady
-
Patent number: 8790700Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.Type: GrantFiled: October 2, 2013Date of Patent: July 29, 2014Assignee: TRIS Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20140205558Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.Type: ApplicationFiled: March 24, 2014Publication date: July 24, 2014Applicant: Hope Medical Enterprises, Inc. dba Hope PharmaecuticalsInventors: Craig Sherman, Catherine Marie Smith, Kevin Robert Wirtz, Erich Schulze
-
Patent number: 8778324Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.Type: GrantFiled: October 9, 2012Date of Patent: July 15, 2014Assignee: Relypsa, Inc.Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Gerrit Klaerner
-
Publication number: 20140154328Abstract: The invention relates to an oral pharmaceutical composition comprising coated particles of a complex of at least one active agent with an ion-exchange resin, wherein said particles are coated with a bioadhesive coating layer comprising at least one bioadhesive material. The invention also relates to a process for preparing the oral pharmaceutical composition.Type: ApplicationFiled: April 5, 2012Publication date: June 5, 2014Inventor: Cvjetko Brkicic
-
Publication number: 20140105848Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding polymer to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.Type: ApplicationFiled: October 8, 2013Publication date: April 17, 2014Applicant: Relypsa, Inc.Inventors: Gerrit Klaerner, Lance Berman
-
Patent number: 8697102Abstract: A solid buffer including one or more ion exchange materials, wherein said solid buffer has a volumetric buffering capacity greater than about 20 mM H+/(L.pH unit) and further wherein, when said material is in an environment capable of transporting H+ ions, said solid buffer is adapted to cause the death of at least one target cell within or in contact with said environment. A selectively permeable barrier layer may be provided covering the solid buffer.Type: GrantFiled: June 25, 2010Date of Patent: April 15, 2014Assignee: Oplon B.V.Inventors: Shmuel Bukshpan, Gleb Zilberstein
-
Publication number: 20140072645Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: July 22, 2013Publication date: March 13, 2014Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell MCMAHEN
-
Publication number: 20140030334Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.Type: ApplicationFiled: October 2, 2013Publication date: January 30, 2014Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20130309191Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: November 30, 2012Publication date: November 21, 2013Inventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Van Well
-
Patent number: 8586097Abstract: The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis.Type: GrantFiled: October 2, 2006Date of Patent: November 19, 2013Assignee: Relypsa, Inc.Inventors: Futian Liu, Han-Ting Chang, Dominique Charmot, Eric Connor, Paul Mansky, Mingjun Liu
-
Patent number: 8586018Abstract: A medium for isolating or releasing an electrostatically charged component from or into an aqueous composition. The medium has a polyelectrolyte film on at least one surface of an article wherein the polyelectrolyte film is characterized by an interpenetrating network of a predominantly positively charged polymer and a predominantly negatively charged polymer. The predominantly positively charged polymer, the predominantly negatively charged polymer or both contain (i) a pH sensitive imidazole repeat unit having a pKa between 3 and 9, or (ii) a redox sensitive repeat unit selected from the group consisting of quaternized bipyridine repeat units, coordinated metal repeat units, pyrrole repeat units, aniline repeat units, thiophene repeat units and combinations thereof having a redox potential between +1.2 volts and ?1.2 volts versus a standard hydrogen electrode.Type: GrantFiled: June 28, 2013Date of Patent: November 19, 2013Inventors: Joseph B. Schlenoff, Zhijie Sui, David S. Salloum, Hassan Rmaile
-
Patent number: 8563447Abstract: Wound care devices having a topically applied silver-based antimicrobial finish are provided. The finish comprises at least one silver ion-containing compound and at least one binder compound. The finish may be applied to a target substrate, such as a fiber, fabric, film, foam, hydrogel, or hydrocolloid to provide a single layer antimicrobial wound care device. Alternatively, a silver-containing layer may be combined with one or more additional layers of target substrate to provide a composite antimicrobial wound care device. The device may also contain an odor-absorbing component capable of reducing or eliminating odors that are inherently associated with infectious wounds. Also provided is a method for making the wound care device and a composition of matter comprising the silver-based antimicrobial finish.Type: GrantFiled: August 14, 2003Date of Patent: October 22, 2013Assignee: Milliken & CompanyInventors: T. Andrew Canada, Robert L. Schuette, Raymond C. Sturm, Kenneth M. Wiencek, Jason L. Kreider
-
Publication number: 20130272992Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.Type: ApplicationFiled: October 9, 2012Publication date: October 17, 2013Inventors: Dominique Charmot, Han-Ting Chang, Gerrit Klaerner, Jerry M. Buysse, Mingjun Liu
-
Publication number: 20130272991Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.Type: ApplicationFiled: October 9, 2012Publication date: October 17, 2013Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Gerrit Klaerner
-
Patent number: 8557288Abstract: The field of the disclosure relates to microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof. Further, the field of the disclosure relates to coatings and scaffolds comprising microparticles and the processes for forming thereof.Type: GrantFiled: August 13, 2009Date of Patent: October 15, 2013Assignee: Washington UniversityInventors: Donald L. Elbert, Michael D. Nichols, Evan A. Scott
-
Publication number: 20130259949Abstract: The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis.Type: ApplicationFiled: May 24, 2013Publication date: October 3, 2013Applicant: Relypsa, Inc.Inventors: Michael J. Cope, Paul Mansky, Futian Liu, Han-Ting Chang, Dominique Charmot, Eric Connor, Kalpesh Biyani, Mingjun Liu, Tony Kwok-Kong Mong, Yan Chen
-
Patent number: 8524212Abstract: The present invention provides a method for the treatment of nonalcoholic steatohepatitis with a pharmaceutically acceptable anion exchange resin such as, for example, colestimide.Type: GrantFiled: April 22, 2008Date of Patent: September 3, 2013Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Etsuko Hashimoto, Makiko Taniai, Keiko Shiratori
-
Methods of formulating and designing liquid drug suspensions containing ion exchange resin particles
Patent number: 8512759Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.Type: GrantFiled: June 7, 2012Date of Patent: August 20, 2013Assignee: Neos Therapeutics, LPInventors: Russell McMahen, Mark Tengler, Michael Sloane, Daniel Lockhart